Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous versus oral furosemide in chronic fluid overload due to heart failure
NL-OMON41092Phase 2Active, not recruiting
- Sponsor
- scPharmaceuticals Inc.
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of furosemide in heart failure (HF) (2 arms), sponsored by scPharmaceuticals Inc. Primary endpoints: Diuresis and Natriuresis and renal clearance. Started Dec 2014; status: active, not recruiting.
02
Drugs
furosemide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NL-OMON41092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41092.